This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chua, M.-S. Articles by Stevens, M. F. G. Search for Related Content PubMed PubMed Citation Articles by Chua, M.-S. Articles by Stevens, M. F. G.

Role of CYP1A1 in Modulation of Antitumor Properties of the Novel Agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in Human Breast Cancer Cells¹

Cancer Research Laboratories, School of Pharmaceutical Sciences, University of Nottingham, Nottingham NG7 2RD, United Kingdom [M-S. C., T. D. B., M. F. G. S.], and Laboratory of Drug Discovery Research and Development, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Frederick, Maryland 21702-1201 [E. K., S. F. S., E. A. S.]

2-(4-Amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) is a candidate antitumor agent with potent and selective activity against human-derived tumor cell lines in vitro and in vivo. Only sensitive cell lines (e.g., MCF-7) were able to accumulate and metabolize DF 203, forming the main inactive metabolite, 2-(4-amino-3-methylphenyl)-6-hydroxybenzothiazole (6-OH 203). Selective metabolism may therefore underlie its antitumor profile. DF 203 6-hydroxylase activity by MCF-7 cells was not constitutive but induced only after pretreatment of cells with DF 203, 3-methylcholanthrene, or ß-naphthoflavone. 6-Hydroxylation was strongly inhibited by either goat antirat cytochrome P450 1A1 (CYP1A1) serum or -naphthoflavone. Both -naphthoflavone and 6-OH 203 abrogated DF 203-induced growth inhibition. Microsomes from genetically engineered human B-lymphoblastoid cells expressing CYP1A1, CYP1B1, or CYP2D6 metabolized DF 203 to 6-OH 203. Immunoblot analysis detected significantly enhanced CYP1A1 protein in a panel of sensitive breast cancer cell lines after exposure to DF 203. Neither constitutive expression nor induction of CYP1A1 protein was detected in nonresponsive breast (HBL 100, MDA-MB-435, and MCF-7/ADR) and prostate (PC 3 and DU 145) cancer cell lines. The expression of CYP1B1 was also modulated by DF 203 in the same sensitive cell lines. However, of the two isoforms, only CYP1A1 activity was irreversibly inhibited by DF 203 and significantly inhibited by 6-OH 203. In sensitive cell lines only, [⁴C]DF 203-derived radioactivity bound covalently to a M_r 50,000, protein which was immunoprecipitated by CYP1A1 antiserum. The covalent binding of [¹⁴C]DF 203 to recombinant CYP1A1 enzyme was NADPH-dependent and reduced by 6-OH 203 and glutathione. CYP1A1 appears essential for the metabolism of DF 203 and may have a pivotal, yet undefined, role in its antitumor activity.

This article has been cited by other articles:

				A. Wallqvist, J. Connelly, E. A. Sausville, D. G. Covell, and A. Monks Differential Gene Expression as a Potential Classifier of 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole-Sensitive and -Insensitive Cell Lines Mol. Pharmacol., March 1, 2006; 69(3): 737 - 748. [Abstract] [Full Text] [PDF]

				E. Brantley, V. Trapani, M. C. Alley, C. D. Hose, T. D. Bradshaw, M. F. G. Stevens, E. A. Sausville, and S. F. Stinson FLUORINATED 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLES INDUCE CYP1A1 EXPRESSION, BECOME METABOLIZED, AND BIND TO MACROMOLECULES IN SENSITIVE HUMAN CANCER CELLS Drug Metab. Dispos., December 1, 2004; 32(12): 1392 - 1401. [Abstract] [Full Text] [PDF]

				C. O. Leong, M. Suggitt, D. J. Swaine, M. C. Bibby, M. F.G. Stevens, and T. D. Bradshaw In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles Mol. Cancer Ther., December 1, 2004; 3(12): 1565 - 1575. [Abstract] [Full Text] [PDF]

				A. Levine-Fridman, L. Chen, and C. J. Elferink Cytochrome P4501A1 Promotes G1 Phase Cell Cycle Progression by Controlling Aryl Hydrocarbon Receptor Activity Mol. Pharmacol., February 1, 2004; 65(2): 461 - 469. [Abstract] [Full Text] [PDF]

				C. D. Hose, M. Hollingshead, E. A. Sausville, and A. Monks Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: A potential surrogate marker for patient sensitivity Mol. Cancer Ther., December 1, 2003; 2(12): 1265 - 1272. [Abstract] [Full Text] [PDF]

				A. Monks, E. Harris, C. Hose, J. Connelly, and E. A. Sausville Genotoxic Profiling of MCF-7 Breast Cancer Cell Line Elucidates Gene Expression Modifications Underlying Toxicity of the Anticancer Drug 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole Mol. Pharmacol., March 1, 2003; 63(3): 766 - 772. [Abstract] [Full Text] [PDF]

				M. J. Kuffel, J. C. Schroeder, L. J. Pobst, S. Naylor, J. M. Reid, S. H. Kaufmann, and M. M. Ames Activation of the Antitumor Agent Aminoflavone (NSC 686288) Is Mediated by Induction of Tumor Cell Cytochrome P450 1A1/1A2 Mol. Pharmacol., July 1, 2002; 62(1): 143 - 153. [Abstract] [Full Text] [PDF]

				T. D. Bradshaw, M. C. Bibby, J. A. Double, I. Fichtner, P. A. Cooper, M. C. Alley, S. Donohue, S. F. Stinson, J. E. Tomaszewjski, E. A. Sausville, et al. Preclinical Evaluation of Amino Acid Prodrugs of Novel Antitumor 2-(4-Amino-3-Methylphenyl)Benzothiazoles Mol. Cancer Ther., February 1, 2002; 1(4): 239 - 246. [Abstract] [Full Text] [PDF]

				A. I. Loaiza-Perez, V. Trapani, C. Hose, S. S. Singh, J. B. Trepel, M. F. G. Stevens, T. D. Bradshaw, and E. A. Sausville Aryl Hydrocarbon Receptor Mediates Sensitivity of MCF-7 Breast Cancer Cells to Antitumor Agent 2-(4-Amino-3-methylphenyl) Benzothiazole Mol. Pharmacol., January 1, 2002; 61(1): 13 - 19. [Abstract] [Full Text] [PDF]